Integrated Pharmacokinetics (PK)/Efficacy, Safety, and Immunogenicity Study to Demonstrate Similarity of JPB898, a Proposed Biosimilar to Nivolumab, to Opdivo® in Combination With Yervoy®
Sandoz
Sandoz
Bristol-Myers Squibb
Polynoma LLC
Novartis
NRG Oncology
Nova Scotia Health Authority
Nektar Therapeutics
Idera Pharmaceuticals, Inc.
Provectus Pharmaceuticals
AB Science
Lisata Therapeutics, Inc.
Alliance for Clinical Trials in Oncology
European Institute of Oncology
Synta Pharmaceuticals Corp.
Saint John's Cancer Institute
European Organisation for Research and Treatment of Cancer - EORTC